Economic burden of bilateral neovascular age-related macular degeneration: Multi-country observational study

PharmacoEconomics

Volumn 26, Issue 1, 2008, Pages 57-73

  Cruess, Alan F ^a   Zlateva, Gergana ^b   Xu, Xiao ^c   Soubrane, Gisèle ^d   Pauleikhoff, Daniel ^e   Lotery, Andrew ^f   Mones, Jordi ^g   Buggage, Ronald ^b   Schaefer, Caroline ^c   Knight, Tyler ^c   Goss, Thomas F ^c  

^a DALHOUSIE UNIVERSITY   (Canada)

^b PFIZER INC   (United States)

^c Covance Market Access Services Inc   (United States)

^d UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^e ST FRANZISKUS HOSPITAL   (Germany)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^g Ocular Microsurgery Institute   (Spain)

Author keywords

Age related macular degeneration, assessment; Cost of illness; Elderly

Indexed keywords

ADULT; AGED; AGING; ARTICLE; CANADA; COMORBIDITY; CONTROLLED STUDY; COST OF ILLNESS; CROSS-SECTIONAL STUDY; DAILY LIFE ACTIVITY; DEMOGRAPHY; ECONOMIC ASPECT; FAMILY; FEMALE; FRANCE; GERMANY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; SOCIOECONOMICS; SPAIN; SPOUSE; UNITED KINGDOM;

EID: 37549039136     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200826010-00006     Document Type: Article

References (32)

1. Ambati J, Ambati BK, Yoo SH, et al. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 2003 May-Jun; 48 (3): 257-93
2. Verma L, Das T, Binder S, et al. New approaches in the management of choroidal neovascular membrane in age-related macular degeneration. Indian J Ophthalmol 2000 Dec; 48 (4): 263-78
3. Desai M, Pratt LA, Lentzner H, et al. Trends in vision and hearing among older Americans: aging trends no. 2. Hyattsville (MD): National Center for Health Statistics, 2001
4. Dargent-Molina P, Favier F, Grandjean H, et al. Fall-related factors and risk of hip fracture: the EPIDOS prospective study. Lancet 1996 Jul 20; 348 (9021): 145-9
5. Lee HK, Scudds RJ. Comparison of balance in older people with and without visual impairment. Age Ageing 2003 Nov; 32 (6): 643-9
6. Ivers RQ, Cumming RG, Mitchell P, et al. Visual impairment and falls in older adults: the Blue Mountain Eye Study. J Am Geriatr Soc 1998 Jan; 46 (1): 58-64
7. Bonastre J, Le Pen C, Soubrane G, et al. The burden of age-related macular degeneration: results of a cohort study in two French referral centres. Pharmacoeconomics 2003; 21 (3): 181-90
8. Sharma S, Bakal J, Brown G, et al. Economic resources utilized in a cohort of patients with age-related macular degeneration [abstract no. 1410]. Annual Meeting of the Association for Research in Vision and Ophthalmology; 2004 Apr 25-29; Fort Lauderdale (FL)
9. Rizzo JA, Friedkin R, Williams CS, et al. Health care utilization and costs in a Medicare population by fall status. Med Care 1998 Aug; 36 (8): 1174-88
10. Schmier JK, Jones ML, Halpern MT. The burden of age-related macular degeneration. Pharmacoeconomics 2006; 24 (4): 319-34
11. Soubrane G, Cruess A, Lotery A, et al. Burden and resource utilization of neovascular AMD: findings of a multicountry study. Arch Ophthalmol 2007; 125 (9): 1249-54
12. Organisation for Economic Co-operation and Development (OECD). Purchasing power parities (PPP) [online]. Available from URL: http://www.oecd.org/ document/47/0,2340,en_2649_34357_36202863_1_1_1_1,00.html [Accessed 2006 Jan 31]
13. French National Authority for Health. Common classification for medical services. Version 2, 2005 [online]. Available from URL: http://www.ccam.sante. fr/ [Accessed 2006 Jan 27]
14. National Association of Sickness Fund Physicians. Uniform value scale (2005) [online]. Available from URL: http://www.kbv.de/ebm2000plus/EBMGesamt.htm [Accessed 2004 Oct 28]
15. Canadian Institute for Health and Information. Analysis of 2003 data from the Canadian MIS Database (CMDB) [online]. Available from URL: http://secure.cihi.ca/cihiweb/dispPage.jsp?cw_page=spend_canmis_e [Accessed 2006 May 17]
16. Centre for Studies in Health Economics and Social Policy (Centre d'Estudis En Economia De La Salut I De La Politica Social SL, SOIKOS). Database for Spanish Health Costs. Version 2.2 [database on CD-ROM]. Barcelona: SOIKOS, 2005
17. Curtis L, Netten A. Unit costs of health and social services 2004. Kent: Personal Social Services Research Unit (PSSRU), University of Kent, 2004
18. Technical Agency for Information on Hospitalization. Program of medicalization of information systems, 2005 [online]. Available from URL: https://www.epmsi.atih.sante.fr/ [Accessed 2006 Jan 27]
19. University Clinic, Münster, Westphalia Wilhelms University Münster. German Diagnosis-Related Group Webgrouper 2005 [online]. Available from URL: http://drg.uni-muenster.de/index.html [Accessed 2005 Oct 28]
20. Ministry of Health and Long-Term Care. Ontario drug benefit formulary/comparative drug index, edition 38, 2004 [online]. Available from URL: http://www.health.gov.on.ca/english/providers/program/drugs/odbf_mn.html [Accessed 2005 Jun 14]
21. Vidal, 2005 [online]. Available from URL: http://www.vidal pro.net [Accessed 2006 Jan]
22. Rote Liste, 2005 [online]. Available from URL: http://www.rote-liste.de [Accessed 2005 Oct 28]
23. British National Formulary 2005 (BNF). Available from URL: http://www.bnf.org [Accessed 2005 Jul 1]
24. Mattson Jack Group. Epidemiology of age-related macular degeneration. St Louis (MO): Mattson Jack Group, 2003. (Data on file)
25. Augood CA, Vingerling JR, de Jong PT, et al. Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EUREYE). Arch Ophthalmol 2006 Apr; 124 (94): 529-35
26. Wang JJ, Mitchell P, Smith W, et al. Bilateral involvement by age related maculopathy lesions in a population. Br J Ophthalmol 1998 Jul; 82 (7): 743-7
27. Organisation for Economic Co-operation and Development (OECD). Health data 2006 [online]. Available from URL: http://www.oecd.org [Accessed 2006 Aug 17]
28. Bonastre J, Le Pen C, Anderson P, et al. The epidemiology, economics and quality of life burden of age-related macular degeneration in France, Germany, Italy and the United Kingdom. Eur J Health Econ 2002; 3 (2): 94-102
29. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006 Oct 5; 355 (14): 1432-44
30. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006 Oct 5; 355 (14): 1419-31
31. Chakravarthy U, Adamis AP, Cunningham Jr ET, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006 Sep; 113 (9): 1508-21
32. Gragoudas ES, Adamis AP, Cunningham Jr ET, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004 Dec 30; 351 (27): 2805-16